Introduction
============

Hematopoietic stem cell transplant (HSCT) is designed to reboot the immune system in many hematological advanced malignant and nonmalignant disorders. Two forms are used: the autologous, which uses the patient as a donor and the allogeneic, which utilizes another compatible individual as the donor ([@b1-ijsc-12-043]). The donated stem cells are derived either from the bone marrow (central HSCT) or from the blood (peripheral HSCT). These methods should be preceded and supported by the administration of chemo-radiotherapy to deplete much of the immune system, suppress the host immune system and prevent graft rejection ([@b2-ijsc-12-043], [@b3-ijsc-12-043]). In addition, the administration of antibiotics and immunosuppressive therapy is performed after HSCT to prevent graft vs. host disease (GVHD). In Jordan, descriptive studies and case reports of HSCT in the pediatric population with immunodeficiency disease and malignancies have been conducted. However, more emphasis on HSCT-related morbidity and mortality in adults is warranted ([@b4-ijsc-12-043], [@b5-ijsc-12-043]).

In general, patients should be hospitalized and monitored for more than 10 days prior to the procedure ([@b3-ijsc-12-043]). Therefore, multidisciplinary care should be directed toward orientation and teaching of the patient and family for early identification of fever, infection, neutropenia, emotional, cognitive and spiritual needs ([@b6-ijsc-12-043], [@b7-ijsc-12-043]). The related-HSCT medication has a toxic effect and produces early and late complications such as acute kidney injury (AKI) despite the type of HSCT. AKI is one of the early medical conditions that could be caused by hemodynamic instability, toxicities of the administered medications and/or conditioning therapy before and after HSCT ([@b5-ijsc-12-043]). Adjustment of the chemotherapy dose, reliable facility services and highly trained personnel have begun to show promising indicators of safety in HSCT therapy ([@b8-ijsc-12-043]). Yet, the incidence of AKI varied widely between reported studies because of various definitions and assessment methodology among patients with peripheral and central HSCT. Findings indicated a high degree of association between AKI and short and long-term mortality ([@b9-ijsc-12-043]--[@b11-ijsc-12-043]). However, incidence and risk factors were not adequately revealed in adult Jordanians who received peripheral HSCT.

The Kidney Disease for Improving Global Outcomes (KDIGO) introduced the RIFLE classification as a sensitive and specific assessment in diagnosing AKI among hospitalized and critically ill patients ([@b12-ijsc-12-043], [@b13-ijsc-12-043]). However, this classification was not applied prospectively to adult patients who underwent HSCT therapy. The vast majority of studies evaluated AKI in pediatric patients who received the HSCT procedure ([@b13-ijsc-12-043], [@b14-ijsc-12-043]). RIFLE was developed to classify acute renal failure (ARF) defined in three grades of severity--Risk (R), Injury (I) and Failure (F). Although a few studies applied this scoring system in patients receiving HSCT, its usefulness in assessing and evaluating outcomes of AKI have shown promising results ([@b11-ijsc-12-043]). The objectives of the present study were 1) to determine the current incidence of post HSCT AKI based on the RIFLE criteria, and 2) to identify AKI risk factors and predict long term complications (e.g. relapse) and death associated with post-HSCT AKI in the HSCT Jordanian center within the University of Jordan Hospital.

Materials and Methods
=====================

A retrospective pilot study was conducted between July 2002 and April 2016 on 140 patients at the HSCT Research Center of the University of Jordan Hospital in Amman, Jordan. Only 70 adult patients were included in the study; children and adolescents were excluded, as well as adult patients with missing data. An informed consent to retrieve and review their data for both clinical and research purposes was obtained from the patients on admission. The inclusion criteria were as follows: age \>18 years and recipient of allo and/or autogeneic transplantation. Data related to patients with hematologic and non-hematologic malignancies that underwent HSCT after a conditioning regimen were obtained for evaluation of frequency and outcome of AKI and its complications. Acute kidney injury was evaluated in patients with allogeneic and autologous HSCT. Grafts were collected from peripheral blood.

Peripheral HSCT protocol
------------------------

All patients were hospitalized for peripheral HSCT. Chemotherapy-conditioning protocols were categorized into groups. The first group received cyclophosphamide 50\~60 mg/kg D1\~D2+fludarabine 30\~35 mg/m^2^ D1\~D3±ATG 3 mg/kg D1\~D3. The second group received melphalan 180 mg/m^2^ D1. The third group received melphalan 80\~130 mg/m^2^ D1+fludarabine 30\~35 mg/m^2^ D1\~D3. The fourth group received melphalan 180 mg/m^2^ D1+VP-16 700\~1200 mg over 2 days OR fludarabine 90\~150 mg over 3 days. The fifth group consisted of others (miscellaneous) ([Table 1](#t1-ijsc-12-043){ref-type="table"}). No patients in the study received radiation therapy. Broad-spectrum antibiotic prophylaxis was used for neutropenia. Antibiotics included vancomycin, gentamycin, acyclovir, colomycin, amikacin, azithromycin, tienam, amphotericin b, targocid, tazocin and cephalosporins.

Risk factors for acute kidney injury
------------------------------------

Patient characteristics at baseline were collected from medical records including age, gender, HSCT type, primary medical diagnosis, body surface area (BSA), body mass index (BMI), gender of the donor in case of allogeneic HSCT, chemotherapy-conditioning protocols, dose of chemotherapy, major complications and the use of nephrotoxic medications. Renal function was followed for 100 days including serum creatinine (SCr) and blood urea nitrogen (BUN).

Renal function was assessed by SCr and mean values of SCr were computed at established time intervals: first, second, and third month after chemotherapy. Estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease Study equation: eGFR (ml/min/1.73 m^2^)=186\*serum creatinine ^−1.154^ \*Age ^−0.203^ \* (0.742 if female)\* (1.212 if African American). The last part of the equation regarding African American did not apply to the Jordanian population. None of the patients were on maintenance dialysis or had received a renal transplant. RIFLE criteria were used to evaluate the severity of AKI. The RIFLE class was determined based on the worst SCr value in a 3-month follow-up period. The change in serum creatinine level was used to classify patients according to the RIFLE criteria. The maximum RIFLE class (risk, injury or failure) of the first 3 months post transplant was considered. The RIFLE criteria include the following four stages: grade 0, no AKI; risk for AKI that corresponded to an SCr×1.5 from baseline; injury that corresponded to an increased SCr×2 from baseline; and failure, that corresponded to an increase×3 from baseline. Baseline measurement of SCr was assessed at the day of chemotherapy. The urine volume criterion was not applied, as it was missing from patients' records.

Impact of AKI stages on prognosis
---------------------------------

Mortality and complications data were collected from the files of the patients during hospitalization or after discharge during follow-up visits. These complications or events included relapse, graft failure, meningitis, acute GVHD, CNS involvement, hemolysis and primary disease progression.

Analysis
--------

Data were presented as mean±standard deviation and frequencies based on variable levels. Comparisons of frequencies between groups were performed using the chi-square test or Fisher's exact test for categorical variables. Median values were compared using the Mann-Whitney U-test. Complications or events were noted at any time following HSCT therapy. Overall survival curves, progression-free survival, and AKI were estimated by the Kaplan-Meier method and compared with the log-rank test. All tests were two-sided with a p value of p=0.05 as statistically significant. Analyses were performed using SPSSs version 21.

Results
=======

Patient baseline characteristics
--------------------------------

The baseline characteristics of the 70 participants are presented in [Table 1](#t1-ijsc-12-043){ref-type="table"}. All the participants received peripheral HSCT. A total of 70 patients with a mean of 32.3 ±11 years (range, 18 to 62 years) were followed. They were 43 males and 27 females. Allograft HSCT was performed for 43 (61.4%), and auto-graft HSCT for 27 (38.6%) participants. The median follow-up time after HSCT was 41 months (range, 0\~173). The underling hematological disease requiring HSCT were chronic myeloid leukemia (n=4), multiple myeloma (n=7), Hodgkin's lymphoma (n=8), non-Hodgkin's lymphoma (n=5), acute lymphatic leukemia (n=8), acute myeloid leukemia (n=14), amyloidosis (n=3), myelodysplastic syndrome (MDS) (n=3), aplastic anemia (n=12) and one case was found in each of the following diseases: myelofibrosis, spinocerebellar ataxia, thalassemia major, paroxysmal nocturnal hemoglobinuria, and osteopetrosis. In all, of 48 patients, 22 (68.6%) developed an event or complication in less than 24 months after HSCT. Twelve (17.1%) relapses occurred at median day 256 (IQR 131\~315, range 64\~4611) after HSCT; 5 (7.1%) cases developed acute GVHD, which occurred at median day 27 (IQR 23.5\~36.5, range 23\~39), and at least one of the following events occurred in a single individual; graft failure, meningitis, primary disease progression, hemolysis and CNS involvement.

Frequency of AKI and risk factors
---------------------------------

Based on RIFLE criteria, in the first month, risk (R) for AKI occurred in 7 (10%) patients, injury (I) was in 2 (2.9%) and kidney failure (F) occurred in one patient. In the second month of follow-up, risk for AKI occurred in 7 (10%) participants, injury (I) of the kidney was noted in 7 (10%) patients and failure occurred in 2 (2.9%) individuals. In the final month, 8 (11.4%) patients were at risk (R) for AKI, 3 (4.3%) injured (I) and no patients had renal failure (F). For the present study, the patients were considered with kidney dysfunction based on the RIFLE criteria if they were detected at any stage within the three months follow-up ([Table 1](#t1-ijsc-12-043){ref-type="table"} and [2](#t2-ijsc-12-043){ref-type="table"}). The estimated glomerular filtration rate mean scores at initial chemotherapy day was 145±67.5 (range, 45 to 325). The mean scores of weekly eGFR of the patients are illustrated in [Fig. 1](#f1-ijsc-12-043){ref-type="fig"}. Risk factors to develop AKI based on RIFLE criteria were chemotherapy protocol type (p=0.02), HSCT type (p=0.001), male gender for donor (p=0.01) and mean value of blood urea nitrogen (p*\<*0.001) ([Table 2](#t2-ijsc-12-043){ref-type="table"}). Of the 27 patients who received allograft HSCT, 8 were at risk for AKI and 10 patients developed AKI or kidney failure. There was no statistical difference between different stages of AKI in relation to age, gender, underlying primary disease, BMI, BSA or usage of nephrotoxic drugs. Patients were on different chemotherapy protocols based on their diagnosis and stages of the primary disease including, melphalan (melphalan 180 mg/m^2^+VP-16 700\~1200 mg or fludarabine 90\~150 mg) or higher doses of melphalan (melphalan 180 mg/m^2^) which was associated with higher risk for AKI compared to other protocols ([Table 2](#t2-ijsc-12-043){ref-type="table"}).

Time to complication and AKI
----------------------------

Kaplan-Meier survival curve of the three categories of AKI (no AKI=stage 0, stages of risk and stages of injury to failure were combined) showed a significant difference in a 12-year survival rate, with the best survival in patients with no AKI (stage 0) and the worst survival in injury or failure on the RIFLE criteria (log rank test, p=0.001). Events or complications happened at an average of 19.3 months in patients with no AKI, and 3.6 months in a risk group and 2 months in patients with injury and failure. It could be speculated that patients with existing AKI based on RIFLE criteria may develop a complication earlier than patients without AKI.

Time to death and AKI
---------------------

The Kaplan-Meier survival curve ([Fig. 2](#f2-ijsc-12-043){ref-type="fig"}) of the three categories of AKI (no AKI=stage 0, stages of risk and stages injury to failure were combined) showed a significant difference in 12 years survival, with the best survival in patients with no AKI (stage 0) and the worse survival in injury or failure on the RIFLE criteria (log rank test, p=0.001). The deaths happened at an average of 130-months in no AKI patients, and 53-months in the *at risk* group and 38-months in patients with AKI and kidney failure. Patients with AKI based on RIFLE criteria died earlier than patients with no AKI ([Fig. 3](#f3-ijsc-12-043){ref-type="fig"}).

Discussion
==========

HSCT is providing a fundamental immunological repair to many individuals with challenging malignant and non-malignant diseases who had no hope with conventional therapies ([@b1-ijsc-12-043], [@b15-ijsc-12-043]). Quality of care should be optimized to achieve excellent patient outcomes through holistic care by the multidisciplinary team ([@b6-ijsc-12-043], [@b7-ijsc-12-043]). The results of this present study suggest that AKI is an early complication that commonly happens in the first 90 days and may have a negative effect on prognosis. The overall incidence of AKI during the 3-month follow-up was 31.6%, which is lower than the rates reported in previous research ([@b12-ijsc-12-043], [@b14-ijsc-12-043]). The KDIGO Clinical Practice Guideline for Acute Kidney Injury introduced the RIFLE criteria-Risk, Injury, and Failure; and the two outcome classes: Loss and End-Stage Renal Disease (ESRD) to define AKI and the severity classes ([@b13-ijsc-12-043]). Many risk factors played a role in deteriorating renal function in different populations ([@b16-ijsc-12-043]), however, patients undergoing the HSCT procedure were rarely investigated. Risk for AKI or failure was significantly correlated with chemotherapy protocol type, HSCT type, donor gender, and blood urea nitrogen. However, BMI and BSA were not different for different stages of kidney dysfunction. Others found that Jordanian patients with ESRD receiving hemodialysis were more likely to have low BMI compared to patients with earlier stages of CKD ([@b16-ijsc-12-043]). Nephrologists and oncology nurse specialists should receive special training in screening, diagnosing, managing and treating AKI in this setting.

According to the most recent criteria on the evaluation and severity of AKI, the incidence among the allogeneic HSCT ranged from 20% to 90% versus \<20% as expected for those undergoing autogenic HSCT ([@b9-ijsc-12-043], [@b10-ijsc-12-043]). These figures correspond with the incidence of AKI in the present study. In the first month, the incidence of AKI was 16.6%, 32% for the second month and 30% for the 3rd month. None of the Jordanian patients had AKI at the time of HSCT, while Shingai and colleagues found an early onset of AKI at the HSCT time which corresponded to 22% of an allogeneic HSCT Japanese sample and 42.7% as a late AKI at 100 days after HSCT ([@b12-ijsc-12-043]). The longer time to AKI occurrence in the peripheral myeloablative HSCT, the less infectious diseases and organ failure rate happened ([@b11-ijsc-12-043]). RIFLE classification was not applied adequately in patients who had undergone HSCT. Biological markers and a test for creatinine clearance should be compared with SCr and urine output as the gold standard markers for kidney function in this population ([@b17-ijsc-12-043], [@b18-ijsc-12-043]).

The present study found that high doses of chemotherapy (melphalan) were associated with AKI. Yet, the incidence of AKI was mild; none of the patients required dialysis. Conditioning chemotherapy is a common risk factor for AKI, in addition to the combined effects of antibiotics and immunosuppressive drugs. However, this conclusion remains debatable based on dose adjustment and usage of drug combination ([@b8-ijsc-12-043], [@b12-ijsc-12-043]). Moreover, it was difficult to determine the actual effects of these nephrotoxic medications, because many different protocols have been used in many settings ([@b8-ijsc-12-043]). It was suggested that uniform guidelines are warranted in HSCT centers that specify alternative conditioning protocols for each disease or condition. Combining many nephrotoxic medications and dosing adjustment should be considered in protocols using cyclosporine and amphoteracin B. Given the nephrotoxic effect of these medications, there was no statistically significant association between AKI and usage of nephrotoxic medications. However, allogeneic HSCT contributed significantly to the occurrence of AKI in comparison to autogeneic HSCT. This indicates indirectly, that nephrotoxic medications such as methotrexate administered to prevent GVHD in allogeneic HSCT clinically, contributed to the development of AKI. Yet, it is worth mentioning that veno-occlusive disease (VOD) of the liver was not within the complication list of the present sample. VOD is a consequence of decreased renal perfusion and 75% of allogeneic HSCT therapy recipients were found to have VOD within the first month of HSCT ([@b16-ijsc-12-043]).

It was clear that the patients' prognosis and outcomes differed based on the severity and timing of AKI. About 5 out of 9 patients (63%) who developed AKI deceased in the current study. Consistently, Chow et al, (2017) found that patients who underwent HSCT were at a higher risk to develop morbidity such as chronic GVHD, relapse of the original disease and hospitalization compared to non-HSCT patients diagnosed with cancer ([@b18-ijsc-12-043]). The HSCT procedure is intended to heal and improve survival rates in patients with malignancies and immunological disorders. The present study indicates patients who received allogeneic HSCT and who were on pre-HSCT high dose chemotherapy (melphalan) were more likely to develop AKI. However, the therapeutic dose of chemotherapy in relation to renal dysfunction is inconsistent among studies ([@b8-ijsc-12-043]). More prospective studies are needed that use limited chemotherapy protocols with HSCT patients ([@b2-ijsc-12-043]).

Conclusions
===========

In summary, the incidence of AKI is significantly and clinically higher in allogeneic than autologous HSCT (49% vs. 9%), However, it is lower than the reported in previous studies. Mortality rates are not increased in autogeneic HCST patients compared to patients' receiving allogeneic HSCT. No patient in the present Jordanian sample had multiple organ dysfunction linked to intense conditioning chemotherapy regimens such as VOD, engraftment syndrome or required dialysis treatment. It is not clear if renal dysfunction is directly associated with poor prognosis or mediated by the effect of conditioning chemotherapy and nephrotoxic drugs. There is a need to develop a survey that follows patients undergoing HSCT procedures in Jordan. The survey is intended to follow current practices and findings for health care providers and stakeholders as updates for better outcomes and prognosis. The RIFLE classification is based on either the SCr or urine output, which is not adequately tested for sensitivity and specificity in patients having HSCT. Therefore, more evidence-based work is needed to assess better biomarkers (cystatin C, interleukin-18) for earlier prediction of possible infections and relapses.
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###### 

Patients characteristics (n=70)

  Variables                                                               Number   (%)     Mean±SD    Median   Min    Max
  ----------------------------------------------------------------------- -------- ------- ---------- -------- ------ ------
  Age (n=70)                                                                               32.3±11    33       18     62
  Gender (n=70)                                                                                                       
   Male                                                                   43       61.4%                              
   Female                                                                 27       38.6%                              
  Medical diagnosis (n=69)                                                                                            
   Nonmalignant                                                           19       28%                                
   Malignant                                                              50       72%                                
  HSCT type (n=70)                                                                                                    
   Auto                                                                   27       38.6%                              
   Allo                                                                   43       61.4%                              
  Donor gender (n=44)                                                                                                 
   Male                                                                   34       77%                                
   Female                                                                 10       23%                                
  Event-free survival (n=41)                                                                                          
   No event recorded                                                      19       46%                                
   With event of complication                                             22       54%                                
  Death (n=49)                                                                                                        
   No                                                                     33       67%                                
   Yes                                                                    16       33 %                               
  AKI based on RIFLE criteria (n=60)                                                                                  
   No AKI                                                                 41       68.3%                              
   Risk                                                                   8        13.3%                              
   Injury                                                                 9        15%                                
   Failure                                                                2        3.3%                               
  Body mass Index (BMI) (n=64)                                                             25.8±5.4   25.7     17.4   45.8
  Body Surface area (BSAm^2^) (n=64)                                                       1.77±0.9   1.72     1.4    2.0
  Blood urea nitrogen (BUN)                                                                34.9±27    27.2     7.5    170
  Conditioning therapy                                                                                                
   Cyclophosphamide 50--60 mg/kg+Fludarabine 30\~35 mg/m^2^±ATG 3 mg/kg   6        8.6%                               
   Melphalan 180 mg/m^2^                                                  29       41.4%                              
   Melphalan 80\~130 mg/m^2^+Fludarabine 30\~35 mg/m^2^                   11       15.7%                              
   Melphalan 180 mg/m^2^+VP-16 700\~1200 mg OR Fludarabine 90\~150 mg     15       21.4%                              
   Other (miscellaneous                                                   9        12.9%                              

###### 

Patients characteristics by RIFLE classifications of AKI (n=70)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                               No AKI (n=41)\       Risk (n=8)\          Injury (n=9)\        Failure (n=2)\       p value
                                                                          Median±SD or n (%)   Median±SD or n (%)   Median±SD or n (%)   Median±SD or n (%)   
  ----------------------------------------------------------------------- -------------------- -------------------- -------------------- -------------------- ---------
  Age (n=70)                                                              35±12.2              27±9.4               33±7.6               21±1.4               NS

  Gender                                                                                                                                                      

   Male (n=36)                                                            25 (61%)             4 (50%)              6 (66.7%)            1 (50%)              NS

   Female (n=24)                                                          16 (39%)             4 (50%)              3 (33.3%)            1 (50%)              

  Chemotherapy                                                                                                                                                

   Cyclophosphamide 50\~60 mg/kg+Fludarabine 30\~35 mg/m^2^±ATG 3 mg/kg   3 (7.3%)             1 (12.5%)            0                    1 (50%)              0.02

   Melphalan 180 mg/m^2^                                                  25 (61%)             1 (12.5%)            2 (22.2%)            0                    

   Melphalan 80\~130 mg/m^2^+Fludarabine 30\~35 mg/m^2^                   5 (12.2%)            4 (50%)              1 (11.1%)            0                    

   Melphalan 180 mg/m^2^+VP-16 700\~1200 mg OR Fludarabine 90\~150 mg     7 (17.1%)            2 (25%)              5 (55.6%)            1 (50%)              

   Other (miscellaneous                                                   1 (2.4%)             0                    1 (11.1%)            0                    

  HSCT type (n=60)                                                                                                                                            

   Auto                                                                   22 (53.7%)           0                    0                    1 (50%)              \<0.001

   Allo                                                                   19 (46.3%)           8 (100%)             9 (100%)             1 (50%)              

  BMI                                                                     25.7±4.5             27±8.3               24±5.5               30.5±10.6            NS

  BSA                                                                     1.8±0.18             1.7±0.2              1.7±0.2              1.8±0.19             NS

  Donor gender (Allo=44)                                                                                                                                      

   Male                                                                   16 (39%)             6 (75%)              9 (100%)             1 (50%)              0.01

   Female                                                                 5 (7.3%)             2 (25%)              0                    1 (50%)              

  Medical diagnosis                                                                                                                                           

   Malignancies                                                           11 (26.8%)           2 (25%)              2 (22.2%)            1 (50%)              NS

   Non-malignancies                                                       30 (73.2%)           6 (75%)              7 (77.8%)            1 (50%)              

  Nephrotoxic drugs                                                                                                                                           

   Nephrotoxic drugs                                                      32 (78%)             6 (75%)              7 (77.8%)            2 (100%)             NS

   No nephrotoxic drugs                                                   7 (18%)              2 (14.3%)            1 (11.1%)            0                    

   Unknown cases                                                          2 (4.9%)             0                    1 (11.1%)            0                    

  Blood urea nitrogen                                                     25.5±11.7            32±15.9              41.4±3.5             127.8±60             0.000

  Survival rate                                                                                                                                               

   Survived                                                               23 (77%)             4 (67%)              3 (38%)              0                    0.09

   Deceased                                                               7 (23.3%)            2 (33.3%)            5 (63%)              1 (100%)             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
